口服塞利尼索作为晚期或复发性子宫内膜癌一线化疗后的维持治疗
ENGOT-EN5/GOG-3055/SIENDO 是一项在 10 个国家 107 个中心开展的随机、前瞻性、多中心、双盲、安慰剂对照 III 期研究,纳入 263 例完成一线铂-紫杉类化疗后获部分或完全缓解的晚期或复发性子宫内膜癌患者,按 2:1 随机分配接受每周一次口服塞利尼索 80 mg 或安慰剂。意向治疗人群的中位无进展生存期(PFS)在塞利尼索组为 5.7 个月 vs 安慰剂组 3.8 个月(HR 0.76,95%CI 0.54–1.08;双侧 P=0.126),未达统计学显著性;在审计分层数据的预设探索性分析中,塞利尼索组 PFS 达到统计学显著性阈值(HR 0.71,95%CI 0.499–0.996;双侧 P=0.049)。
要点
- 意向治疗人群 PFS:塞利尼索组 5.7 个月 vs 安慰剂组 3.8 个月,HR 0.76(95%CI 0.54–1.08),双侧 P=0.126,未达统计学显著。
- 审计分层数据的预设探索性分析中,塞利尼索组 PFS 达统计学显著阈值(HR 0.71;95%CI 0.499–0.996;双侧 P=0.049)。
- TP53 野生型子宫内膜癌患者中,塞利尼索组与安慰剂组的中位 PFS 分别为 13.7 个月和 3.7 个月。
核心结论
- PFS 的显著性水平仅在审计分析中达到;对 TP53 野生型子宫内膜癌预设探索性亚组的初步分析显示,塞利尼索维持治疗呈现出有希望的结果。
研究设计与样本
- ENGOT-EN5/GOG-3055/SIENDO 是一项在 10 个国家 107 个中心开展的随机、前瞻性、多中心、双盲、安慰剂对照 III 期研究。
- 纳入 18 岁及以上、组织学确诊的子宫内膜癌患者,所有患者均已完成单线至少 12 周的紫杉类-铂类联合化疗并达到部分或完全缓解。
- 2018 年 1 月至 2021 年 12 月间共随机分配 263 例患者,塞利尼索组 174 例,安慰剂组 89 例(2:1 随机分配)。
- 塞利尼索组接受每周一次口服塞利尼索 80 mg,安慰剂组接受安慰剂。
主要发现
- 意向治疗人群中,塞利尼索组中位 PFS 为 5.7 个月(95%CI 3.81–9.20),安慰剂组为 3.8 个月(95%CI 3.68–7.39),HR 0.76(95%CI 0.54–1.08),双侧 P=0.126,未达统计学显著性标准。
- 发现 7 例(2.7%)患者的化疗反应分层数据不正确。
- 在审计分层数据的预设探索性 PFS 分析中,塞利尼索组达到统计学显著性阈值(HR 0.71;95%CI 0.499–0.996;双侧 P=0.049)。
- TP53 野生型子宫内膜癌患者中,塞利尼索组与安慰剂组的中位 PFS 分别为 13.7 个月和 3.7 个月。
- 最常见的 3 级治疗相关不良事件为恶心(9%)、中性粒细胞减少(9%)和血小板减少(7%)。
局限性
- 在意向治疗人群中,PFS 的显著性标准未达到(HR 0.76;95%CI 0.54–1.08;双侧 P=0.126)。
- 发现 7 例(2.7%)患者的化疗反应分层数据不正确。
- TP53 野生型亚组结果为预设探索性亚组的初步分析结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Selinexor inhibits exportin-1 (XPO1) resulting in nuclear accumulation of tumor suppressor proteins including p53 and has clinical activity in endometrial cancer (EC). The primary end point was to assess progression-free survival (PFS) with once-weekly oral selinexor in patients with advanced or recurrent EC. PATIENTS AND METHODS: ENGOT-EN5/GOG-3055/SIENDO was a randomized, prospective, multicenter, double-blind, placebo-controlled, phase III study at 107 sites in 10 countries. Patients 18 years or older with histologically confirmed EC were enrolled. All had completed a single line of at least 12 weeks of taxane-platinum combination chemotherapy and achieved partial or complete response. Patients were assigned to receive 80 mg oral selinexor once weekly or placebo with 2:1 random assignment (ClinicalTrials.gov identifier: NCT03555422). RESULTS: Between January 2018 and December 2021, 263 patients were randomly assigned, with 174 allocated to selinexor and 89 to placebo. The median PFS was 5.7 months (95% CI, 3.81 to 9.20) with selinexor versus 3.8 months (95% CI, 3.68 to 7.39) with placebo (hazard ratio [HR], 0.76 [95% CI, 0.54 to 1.08]; two-sided P = .126), which did not meet the criteria for statistical significance in the intent-to-treat population. Incorrect chemotherapy response stratification data for 7 (2.7%) patients were identified. In a prespecified exploratory analysis of PFS in audited stratification data, PFS for selinexor met the threshold for statistical significance (HR, 0.71; 95% CI, 0.499 to 0.996; two-sided P = .049). Furthermore, patients with the TP53 wild-type (wt) EC had a median PFS of 13.7 and 3.7 months with selinexor and placebo. The most common grade 3 treatment-related adverse events were nausea (9%), neutropenia (9%), and thrombocytopenia (7%). CONCLUSION: The significance level for PFS was only met in the audited analysis. However, a preliminary analysis of a prespecified exploratory subgroup of patients with TP53wt EC showed promising results with selinexor maintenance therapy.
引用
- Vergote I, Pérez-Fidalgo JA, Hamilton EP, et al. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer. J Clin Oncol. 2023. PMID: 37669480. doi:10.1200/JCO.22.02906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。